At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LBPH Longboard Pharmaceuticals, Inc.
Halted 02-25 16:42:55 EST
59.98
+0.00
0.00%
High59.98
Low59.98
Vol0.00
Open59.98
D1 Closing59.98
Amplitude0.00%
Mkt Cap2.34B
Tradable Cap1.57B
Total Shares39.05M
T/O39.33M
T/O Rate0.00%
Tradable Shares26.11M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
data is loading...
Hold Rating for Longboard Pharmaceuticals Amidst Acquisition Uncertainty and Speculative Risks
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. Its lead product candidate is LP352, which is in Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. The company's preclinical product candidate includes LP659 which focuses on developing therapies for multiple neurological diseases; and LP143. It also entered into license agreement with Arena Pharmaceuticals Inc. to develop and commercialize LP352, LP659, LP143, and other compounds. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.